Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Biological and Pharmaceutical Bulletin

• Publication date

  2005-09-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1248/BPB.28.1805PMID 16141567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam

  2009cited by this paper
• No inhibition of cytochrome P450 activities in human liver microsomes by sulpiride, an antipsychotic drug.

  2005cited by this paper
• Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs

  2005cited by this paper
• ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION

  2004cited by this paper
• Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors.

  2004cited by this paper
• Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

  2004cited by this paper
• Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

  2004cited by this paper
• IDENTIFICATION AND CHARACTERIZATION OF POTENT CYP3A4 INHIBITORS IN SCHISANDRA FRUIT EXTRACT

  2004cited by this paper
• Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen.

  2003cited by this paper
• In vitro activation of 7-benzyloxyresorufin O-debenzylation and nifedipine oxidation in human liver microsomes

  2003cited by this paper
• Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration.

  2003cited by this paper
• Voriconazole: A New Triazole Antifungal Agent

  2003cited by this paper
• Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.

  2002cited by this paper
• Drug interactions of micafungin in vitro

  2002cited by this paper
• Inhibition of cytochromes P450 by antifungal imidazole derivatives.

  2002cited by this paper
• Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4.

  2002cited by this paper
• Micafungin sodium (FK-463).

  2002cited by this paper
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cited by this paper
• Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

  2002cited by this paper
• Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit

  2001cited by this paper
• Effects of the Antifungal Agents on Oxidative Drug Metabolism

  2000cited by this paper
• Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil.

  2000cited by this paper
• Assessment of the Quality and Quantity of Drug‐Drug Interaction Studies in Recent NDA Submissions: Study Design and Data Analysis Issues

  1999cited by this paper
• Interaction between fluconazole and midazolam in intensive care patients

  1999cited by this paper
• Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients.

  1999cited by this paper
• Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).

  1999cited by this paper
• Is the role of the small intestine in first-pass metabolism overemphasized?

  1999cited by this paper
• In vitro assessment of human cytochrome P450.

  1998cited by this paper
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications

  1998cited by this paper
• Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents.

  1998cited by this paper
• Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.

  1997cited by this paper
• The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam

  1996cited by this paper
• Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.

  1996cited by this paper
• Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.

  1996cited by this paper
• Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents

  1996cited by this paper
• Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins.

  1996cited by this paper
• Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor.

  1995cited by this paper
• Clinical Pharmacokinetics of Fluconazole

  1993cited by this paper
• Characterization of human cytochrome P450 enzymes

  1992cited by this paper
• Effect of fluconazole on the disposition of phenytoin

  1991cited by this paper
• Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans.

  1990cited by this paper
• Molecular genetics of the P-450 superfamily.

  1990cited by this paper
• Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene.

  1990cited by this paper

• New insights into metabolism of desogestrel in humans using liver microsomes and an HPLC/UV method

  2026cites this paper
• Analysis of adverse events induced by fluconazole based on FAERS database.

  2025cites this paper
• Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation

  2025cites this paper
• Population pharmacokinetics and bioavailability of tacrolimus oral suspension in children with haematopoietic stem cell transplant

  2025cites this paper
• Adverse Drug–Drug Interaction Between Phenobarbital and Fluconazole in Two Dogs

  2025cites this paper
• Association of Omeprazole‐Related Myopathy With Drug–Drug and Drug–Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case–Control Study

  2025cites this paper
• A Review on New Frontiers in Drug-Drug Interaction Predictions and Safety Evaluations with In Vitro Cellular Models

  2025cites this paper
• Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3

  2025cites this paper
• The Impact of Genetic Polymorphisms on the Clinical Efficacy of Azole Antifungals

  2025cites this paper
• The impact of CYP3A5, NR1I2, and POR polymorphisms on tacrolimus dose-adjusted concentration and clinical outcomes in adult allogeneic haematopoietic stem cell transplantation

  2025cites this paper
• Environmental Fate of the Azole Fungicide Fluconazole and Its Persistent and Mobile Transformation Product 1,2,4-Triazole.

  2025cites this paper
• Hypercalcemia in children with APL caused by interactions between voriconazole and all-trans retinoic acid: A case report and literature review

  2025cites this paper
• HLM chip - A microfluidic approach to study the mechanistic basis of cytochrome P450 inhibition using immobilized human liver microsomes.

  2024cites this paper
• Neurotoxicity Related to Multidrug Association: A Case Report

  2024cites this paper
• Simultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction.

  2024cites this paper
• Specific Antidermatophytic Activity of Trifluoromethylthiolated Cinnamate Derivatives: A New Approach to the Therapy of Superficial Fungal Infections of the Skin

  2024cites this paper
• Potential Drug-Drug Interactions with Adefovir Dipivoxil: Clinical Implications and Management Strategies

  2024cites this paper
• Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical Insights

  2024cites this paper
• Rescue Therapy for Supratherapeutic Concentrations of Calcineurin Inhibitors Using Potent Cytochrome P450 Inducers

  2024influential citation
• Model-Based Dose Selection of a Sphingosine-1-Phosphate Modulator, Etrasimod, in Patients with Various Degrees of Hepatic Impairment

  2024cites this paper
• Lower micromolar activity of the antifungal imidazoles on the bacterial-type bifunctional aldehyde/alcohol dehydrogenase (AdhE) in Cryptosporidium parvum and in vitro efficacy against the zoonotic parasite

  2024cites this paper
• Selective steroidogenic cytochrome P450 haem iron ligation by steroid-derived isonitriles

  2023cites this paper
• Successful treatment of hepatitis C virus infection in patients on anti‐epileptics or mood stabilizers using pharmacokinetic enhancers

  2023cites this paper
• Saliva as a noninvasive sampling matrix for therapeutic drug monitoring of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation: A prospective population pharmacokinetic and simulation study

  2023cites this paper
• Characterization of Enzymes Involved in Nintedanib Metabolism in Humans

  2023cites this paper
• Recommendations on the use of azole antifungals in hematology-oncology patients

  2023cites this paper
• Quantitation of Venetoclax in Human Plasma by High-Performance Liquid Chromatography with Ultraviolet Detection.

  2022cites this paper
• Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism

  2022cites this paper
• Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors.

  2022cites this paper
• Characterizing and Quantifying Extrahepatic Metabolism of (−)-Δ9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, (±)-11-Hydroxy-Δ9-THC (11-OH-THC)

  2022influential citation
• Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B

  2022cites this paper
• Nanoliposomes as Drug Delivery Systems for Antifungal Therapy

  2022cites this paper
• The Anti-Fungal Activity of Nitropropenyl Benzodioxole (NPBD), a Redox-Thiol Oxidant and Tyrosine Phosphatase Inhibitor

  2022cites this paper
• Clinical Characteristics of Transplant Recipients Infected with Talaromyces Marneffei: 2 Case Reports and a Literature Review

  2022cites this paper
• Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax

  2022influential citation
• Protoporphyrin IX Associated with Visible Light for the Treatment of Trichophyton rubrum Causing Onychomycosis - An Updated Review

  2022cites this paper
• Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions

  2022cites this paper
• Cytochrome P450 genes mediated by DNA methylation are involved in the resistance to hidradenitis suppurativa.

  2022cites this paper
• Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor

  2022cites this paper
• Antifungal agents, yeast abundance and diversity in surface water: Potential risks to water users.

  2021cites this paper
• The Effects of Voriconazole on Metabolism of All-Trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia: A Case Report

  2021cites this paper
• Isobolographic in vitro interactions of fluconazole with citrus essential oils against Cladosporium cladosporioides

  2021cites this paper
• An Adverse Outcome Pathway on the disruption of retinoic acid metabolism leading to developmental Craniofacial Defects.

  2021cites this paper
• Investigating the Contribution of Drug-Metabolizing Enzymes in Drug-Drug Interactions of Dapivirine and Miconazole

  2021cites this paper
• Current approaches and future strategies for the implementation of pharmacogenomics in the clinical use of azole antifungal drugs

  2021cites this paper
• Commonly Prescribed Medications that Affect Clotting: A Comprehensive Overview

  2021cites this paper
• The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles

  2021cites this paper
• Synthesis and Antileishmanial Evaluation of Arylimidamide-Azole Hybrids Containing a Phenoxyalkyl Linker.

  2021cites this paper
• Revisiting CYP2C9-Mediated drug-drug Interactions: A Review

  2021cites this paper
• In vivo active organometallic-containing antimycotic agents

  2021cites this paper
• Arzneimittelinteraktionen in der Intensivmedizin

  2020cites this paper
• Arzneimittelinteraktionen in der Intensivmedizin

  2020cites this paper
• Antifungal Therapy: New and Evolving Therapies

  2020cites this paper
• Dietary Polyphenols Inhibit the Cytochrome P450 Monooxygenase Branch of the Arachidonic Acid Cascade with Remarkable Structure-Dependent Selectivity and Potency.

  2020cites this paper
• Clinical pharmacology of fluconazole in infants and children

  2020cites this paper
• Clinical analysis of the effects of azole antifungal agents on the anticoagulant activity of warfarin

  2020cites this paper
• Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design.

  2020cites this paper
• Comparison of the inhibitory effect of ketoconazole, voriconazole, fluconazole, and itraconazole on the pharmacokinetics of bosentan and its corresponding active metabolite hydroxy bosentan in rats

  2020cites this paper
• Serum 4β-hydroxycholesterol increases during fluconazole treatment

  2020cites this paper
• Pharmacokinetic Drug-drug Interaction of Antibiotics Used in Sepsis Care in China.

  2020cites this paper
• Differential impacts of azole antifungal drugs on the pharmacokinetic profiles of dasatinib in rats by LC-MS-MS.

  2020cites this paper
• Inhibition and induction of CYP enzymes in humans: an update

  2020cites this paper
• Antimycotic treatment of oral candidiasis in warfarin users.

  2020cites this paper
• Efficacy of posaconazole for treatment of nodular basal cell carcinoma

  2020cites this paper
• A dual system platform for drug metabolism: Nalbuphine as a model compound.

  2019cites this paper
• The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes

  2019cites this paper
• Photochemical and Pharmacokinetic Characterization of Orally Administered Chemicals to Evaluate Phototoxic Risk.

  2019cites this paper
• Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling.

  2019cites this paper
• Use of Micafungin for the Management of a Cluster of Invasive Aspergillosis in Children with Cancer

  2019cites this paper
• Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.

  2019cites this paper
• Clinically significant drug‐drug interaction between tacrolimus and fluconazole in stable renal transplant recipient and literature review

  2019cites this paper
• Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking.

  2019cites this paper
• Predicting the Effects of Different Triazole Antifungal Agents on the Pharmacokinetics of Tamoxifen

  2019cites this paper
• Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects

  2019cites this paper
• Micafungin prophylaxis in routine medical practice in adult and pediatric patients with hematological malignancy: a prospective, observational study in France.

  2019cites this paper
• In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes: stereoselective inhibition of CYP3A

  2019cites this paper
• Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism

  2019cites this paper
• A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009.

  2018cites this paper
• Tolerability profile of the current antifungal armoury

  2018cites this paper
• Drug-drug interaction and doping: Effect of non-prohibited drugs on the urinary excretion profile of methandienone.

  2018cites this paper
• Voriconazole greatly increases the exposure to oral buprenorphine

  2018cites this paper
• Intravenous Haldol Induced Seizures in an Agitated Patient on Scheduled Low Dose Risperidone

  2018cites this paper
• Review of Major Drug-Drug Interactions in Thoracic Transplantation

  2018cites this paper
• KINETICS OF CYCLOPHOSPHAMIDE METABOLISM IN HUMAN, DOG, CAT, AND MOUSE AND RELATIONSHIP TO CYTOTOXIC ACTIVITY AND PHARMACOKINETICS

  2018influential citation
• Pharmacokinetic Interactions and Pharmacogenetics of Clopidogrel, Prasugrel and Ticagrelor

  2018cites this paper
• Quantitative prediction of the extent of drug–drug interaction using a physiologically based pharmacokinetic model that includes inhibition of drug metabolism determined in cryopreserved hepatocytes

  2018cites this paper
• Design, synthesis and evaluation of benzoheterocycle analogues as potent antifungal agents targeting CYP51.

  2018cites this paper
• Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics

  2018influential citation
• Different inhibitory effects of azole-containing drugs and pesticides on CYP2C9 polymorphic forms: An in vitro study.

  2018cites this paper
• Translational High‐Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models

  2018cites this paper
• Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A‐catalysed hydroxylation by sulfaphenazole

  2018influential citation
• Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers.

  2018cites this paper
• [Quantitative Prediction of Drug-Drug Interaction Caused by CYP Inhibition and Induction from In Vivo Data and Its Application in Daily Clinical Practices-Proposal for the Pharmacokinetic Interaction Significance Classification System (PISCS)].

  2018cites this paper
• Evaluation of the effect of fluconazole on the pharmacokinetics of cyclosporin A in healthy dogs after a single dose and at steady-state.

  2017cites this paper
• Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone

  2017cites this paper
• CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations

  2017cites this paper
• Autoinhibitory properties of the parent but not of the N‐oxide metabolite contribute to infusion rate‐dependent voriconazole pharmacokinetics

  2017cites this paper
• Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug–drug interactions in rat liver

  2017cites this paper
• Weakness and pain in arms and legs · dark urine · history of vertebral osteomyelitis · Dx?

  2017cites this paper
• Significance of monitoring plasma concentration of voriconazole in a patient with liver failure

  2017cites this paper